Overview

This trial is active, not recruiting.

Condition loco-regional esophageal cancer
Treatments bevacizumab, paclitaxel, cisplatin, 5-fluorouracil, radiation therapy, esophagectomy
Phase phase 2
Target VEGF
Sponsor University of Michigan Cancer Center
Collaborator Genentech
Start date June 2007
End date June 2013
Trial size 6 participants
Trial identifier NCT00570531, HUM 8625, UMCC 2006.117

Summary

The purpose of this study is to determine whether bevacizumab can improve the outcome of treatment for patients with esophageal cancer whose disease is confined to the esophagus or the closely surrounding lymph nodes.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Measure
The primary outcome that will be measured is the length of time that patients are alive without recurrence of cancer following this therapy.
time frame: 5 years

Secondary Outcomes

Measure
Determination of whether the pre-operative treatment can eliminate all the cancer cells at the time of surgery.
time frame: 1 year
To assess the toxicity of this regimen.
time frame: Every three weeks for one year

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: 1. No prior treatment for esophageal cancer 2. No prior radiation to the chest or upper abdominal area 3. No prior treatment with an EGFR inhibitor or an anti-angiogenic agent 4. Disease should be limited to the esophagus and regional lymph nodes - Exclusion Criteria: 1. History of stroke 2. History of heart attack 3. Inadequately controlled high blood pressure

Additional Information

Official title Phase II Trial of Pre-Operative Chemoradiation Plus Bevacizumab, Followed by Surgery, and Post-Operative Adjuvant Bevacizumab for Patients With Loco-Regional Esophageal Carcinoma
Principal investigator Susan Urba, MD
Description Standard treatment is pre-operative chemotherapy and radiation, followed by surgery. In this study, bevacizumab will be added to the pre-operative chemotherapy and radiation, and then bevacizumab will also be administered for a year after surgery. Bevacizumab is a humanized monoclonal antibody (a type of protein that is normally made by the immune system to help defend the body from infection and cancer) produced by Genentech, Inc. using recombinant DNA technology. Bevacizumab has been approved by the FDA for the treatment of metastatic colorectal cancer in combination with chemotherapy. Bevacizumab is experimental in the treatment of esophageal cancer and has not been approved by the FDA for the treatment of esophageal cancer. Bevacizumab is an antibody directed against vascular endothelial growth factor, or VEGF. VEGF is a growth factor with a well defined role in normal and abnormal blood vessel formation. It is present in a wide variety of normal tissues, but is produced in excess by most solid cancers (tumors). In the setting of cancer, VEGF promotes the growth of blood vessels that bring nutrients to tumor cells. In studies with laboratory animals, bevacizumab inhibits the growth of several different types of human cancer cells, including colon cancer cells, by blocking the effects of VEGF. By blocking VEGF, your doctors hope that bevacizumab may decrease blood supply to the tumor, and therefore decrease the ability of the tumor to grow and come back after chemotherapy, radiation, and surgery.
Trial information was received from ClinicalTrials.gov and was last updated in March 2013.
Information provided to ClinicalTrials.gov by University of Michigan Cancer Center.